Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS
暂无分享,去创建一个
[1] P. Reddy,et al. Recent Advances in Novel Drug Delivery Systems , 2003 .
[2] Li,et al. Transport, metabolism and elimination mechanisms of anti-HIV agents. , 1999, Advanced drug delivery reviews.
[3] D. Faulds,et al. Saquinavir , 1996, Drugs.
[4] N. Bleyzac,et al. Simple and rapid high-performance liquid chromatographic method for nelfinavir, M8 nelfinavir metabolite, ritonavir and saquinavir assay in plasma. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[5] M. Vert,et al. A Novel Route To Poly(ε-caprolactone)-Based Copolymers via Anionic Derivatization , 2000 .
[6] Mansoor M. Amiji,et al. BIODEGRADABLE POLY (E-CAPROLACTONE) NANOPARTICLES FOR TUMOR-TARGETED DELIVERY OF TAMOXIFEN , 2002 .
[7] K. Kedzierska,et al. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. , 2002, Current medicinal chemistry.
[8] M. Amiji,et al. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. , 2005, International journal of pharmaceutics.
[9] R. Kim. Drug transporters in HIV Therapy. , 2003, Topics in HIV medicine : a publication of the International AIDS Society, USA.
[10] J. Beijnen,et al. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. , 2001, Molecular pharmacology.
[11] A. Rabson,et al. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. , 2004, Bioconjugate chemistry.
[12] V. Labhasetwar,et al. Targeting intracellular targets. , 2004, Current drug delivery.
[13] A. Kabanov,et al. New technologies for drug delivery across the blood brain barrier. , 2004, Current pharmaceutical design.
[14] V. Préat,et al. Stability study of nanoparticles of poly(epsilon-caprolactone), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). , 1996, Biomaterials.
[15] J. Batsis. Clinical Pharmacology of Protease Inhibitors In HIV Infection , 2000 .
[16] F. Gimenez,et al. Transport of HIV Protease Inhibitors Through the Blood-Brain Barrier and Interactions With the Efflux Proteins, P-Glycoprotein and Multidrug Resistance Proteins , 2004, Journal of acquired immune deficiency syndromes.
[17] G. Ponchel,et al. Combined hydroxypropyl-beta-cyclodextrin and poly(alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. , 2001, International journal of pharmaceutics.
[18] Dipak K. Sarker. Engineering of nanoemulsions for drug delivery. , 2005, Current drug delivery.
[19] R. Femia,et al. The science of megestrol acetate delivery: potential to improve outcomes in cachexia. , 2005, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[20] Shigeru Tsuchiya,et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1) , 1980, International journal of cancer.
[21] M. Amiji,et al. Poly(ethylene oxide)-modified poly(ɛ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer , 2005 .
[22] X Huang,et al. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[23] H. von Briesen,et al. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro , 1996, Antimicrobial agents and chemotherapy.
[24] M. Amiji,et al. Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. , 2002, International journal of pharmaceutics.
[25] M. Cima,et al. Nondestructive and on-line monitoring of tablets using light-induced fluorescence technology , 2004, AAPS PharmSciTech.
[26] Mansoor M. Amiji,et al. Cellular uptake and concentrations of tamoxifen upon administration in poly(ε-caprolactone) nanoparticles , 2003, AAPS PharmSci.
[27] C. Flexner. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. , 2000, Annual review of pharmacology and toxicology.